ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 189 entries already.
From its all-time high in August 2021 the largest and most important index for the biotech industry also in Europe (NBI) lost around 25%. After a period of excessive capital inflows, money is much harder to come by these days. The answer can only be more creativity in structuring deals.
DSP?Tosoh Bioscience recently launched Octave© BIO, the first in a series of MCC instruments
targeting all stages of biomolecule manufacturing. Here, Tosoh discusses the potential of MCC to help alleviate downstream bottlenecks and a process intensification collaboration they recently performed with Catalent Biologics. Emily Schirmer, Interim General Manager at Catalent Biologics, provides selected insights on Catalents findings from the collaboration.
DSP Tosoh Bioscience recently launched Octave© BIO, the first in a series of MCC instruments
targeting all stages of biomolecule manufacturing. Here, Tosoh discusses the potential of MCC to help alleviate downstream bottlenecks and a process intensification collaboration they recently performed with Catalent Biologics. Emily Schirmer, Interim General Manager at Catalent Biologics, provides selected insights on Catalent’s findings from the collaboration.
In a world where biotechnology has been enabling products and processes for decades, it’s time to step out from behind the technology and claim the resulting products and their value in our everyday life. It needs higher visibility and recognition of impact, moving beyond its ‘enabling’ brand which forever makes it sound like the benefits are just around the corner, rather than the existing significant economic and industrial impact.
The Supervisory Board of Bayer AG has appointed Roche Pharmaceuticals CEO Bill Anderson (56) as new Chairman of the Management Board of Bayer AG with effect from 1 June 2023.
Former Rentschler-CEO Dr Frank Mathias officially takes up his new position as CEO and board member of Oxford Biomedica at the end of March.
Dr Mark Chadwick will bring extensive industry knowledge to his new role as Strategic Business Advisor at UK-based Ingenza Ltd.
France-based Abivax SA announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as its new Chief Medical Officer. He will assume the new role in the beginning of March.
Dr Carole Nicco took up her position as CSO of Belgium-based BioSenic in mid-January. Nicco will oversee the development of BioSenic’s cell therapy and autoimmune disease platform pipeline and be responsible for R&D programmes.
At the beginning of January 2023?Marjut Falkstedt will start as new Chief Executive of the European Investment Fund (EIF).